+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Lipid Disorder Treatment Market - Growth, Trends, and Forecast (2020 - 2025)

  • ID: 4896231
  • Report
  • January 2020
  • Region: Global
  • 109 pages
  • Mordor Intelligence
UP TO OFF
until Jun 30th 2020
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Astrazeneca Plc
  • Merck & Co.
  • Novartis AG
  • Pfizer, Inc
  • Ranbaxy Laboratories Ltd.
  • Teva Pharmaceuticals
  • MORE
Market Overview

The lipid disorder treatment market studied was projected to grow with a CAGR of nearly 7.8% during the forecast period. The major factors attributing to the growth of the lipid disorder treatment market are the growing prevalence of lifestyle diseases like obesity and increasing smoking and alcohol consumption. The lifestyle diseases are conditions associated with the way the people live. They include atherosclerosis, heart disease, stroke, obesity, and type 2 diabetes. According to the World Health Organization (WHO) in 2016, 39% of women and 39% of men aged 18 and over were overweight. Furthermore, the Increasing growth of familial combined hyperlipidemia incidence rate also plays a major role in the growth of the market. However, the side effects of the medication involved in the treatment are the restraint to the growth of the market.

Scope of the Report

According to the scope of the report lipid disorders comprise a broad spectrum of conditions where the blood lipid levels are affected. Generally, it is associated with an increase in the blood lipid levels. This report is segmented by Indication, by Distribution Channel, and by Geography.

Key Market Trends

Familial Combined Hyperlipidemia incidence rate to grow and generate more revenue in the coming years
  • Familial combined hyperlipidemia is the most common congenital disorder that increases blood fats. It causes high cholesterol and high blood triglycerides which can cause early heart attacks.
  • The rate of incidence of this disease is high in adults, and the treatment market for the disease is profitable for the key players involved in the manufacturing of the drugs. As this condition is common, the drugs for this disease has maximum sales and generates maximum revenue. Statins are the class of drugs that are used to treat familial combined hyperlipidemia, the same is used to treat related conditions like obesity. Therefore as the incidence of obesity increases the market growth rate of this segment also increases.
  • As per the National Organization for Rare Disorders(NORD), 1 in 220 people have familial combined hyperlipidemia and these statistics prove that the increasing patient pool is directly proportional to the market growth.
North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall lipid disorder treatment market, throughout the forecast period. The market growth is due to the factors such as the presence of key players, high prevalence of obesity and other lifestyle disorders in the region, established healthcare infrastructure, are some of the key factors accountable for its large share in the market. Furthermore, higher incidence of familial combined hyperlipidemia, beneficial government initiatives and increase awareness of the treatment are some of the drivers expected to increase the market growth. In the North America region, the United States holds the largest market share. According to the Center for Chronic Disease Prevention (CDC), 7% of U.S. children and adolescents ages 6 to 19 have high total cholesterol, therefore a growing number of these diseases in the country are anticipated to stimulate the demand in this region.

Competitive Landscape

The lipid disorder treatment market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market Pfizer, Inc, Novartis AG, AstraZeneca Plc, Merck & Co., Inc., Sun Pharma, Emcure Pharmaceuticals, Teva Pharmaceuticals, Mylan Pharmaceuticals, Inc., Kowa Pharmaceuticals America, Inc., Glenmark Pharmaceuticals Ltd., Wockhardt Limited.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format.
  • Report customization as per the client's requirements.
  • 3 months of analyst support.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Astrazeneca Plc
  • Merck & Co.
  • Novartis AG
  • Pfizer, Inc
  • Ranbaxy Laboratories Ltd.
  • Teva Pharmaceuticals
  • MORE
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increase in Prevalence of Several Lifestyle Diseases
4.2.2 Rise in the Smoking and Alcohol Consumption
4.3 Market Restraints
4.3.1 Side effects of the treatment
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Indication
5.1.1 Hypercholesterolemia
5.1.2 Dysbetalipoproteinemia
5.1.3 Familial Combined Hyperlipidemia
5.1.4 Others
5.2 By Distribution Channel
5.2.1 Hospital Pharmacies
5.2.2 Retail Pharmacies
5.2.3 Online Pharmacies
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Pfizer, Inc
6.1.2 Novartis AG
6.1.3 Astrazeneca Plc
6.1.4 Merck & Co.
6.1.5 Emcure Pharmaceuticals Ltd.
6.1.6 Ranbaxy Laboratories Ltd.
6.1.7 Teva Pharmaceuticals
6.1.8 Mylan Pharmaceuticals, Inc.
6.1.9 Kowa Pharmaceuticals America, Inc.
6.1.10 Glenmark Pharmaceuticals Ltd.
6.1.11 Sun Pharmaceuticals Industries Ltd.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Pfizer, Inc
  • Novartis AG
  • Astrazeneca Plc
  • Merck & Co.
  • Emcure Pharmaceuticals Ltd.
  • Ranbaxy Laboratories Ltd.
  • Teva Pharmaceuticals
  • Mylan Pharmaceuticals, Inc.
  • Kowa Pharmaceuticals America, Inc.
  • Glenmark Pharmaceuticals Ltd.
  • Sun Pharmaceuticals Industries Ltd.
Note: Product cover images may vary from those shown
Adroll
adroll